User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

Primary tabs

Compston, J. Devogelaer, Jean-Pierre [UCL] Reid, D. M. Boisdron, J. Brandi, M. -L. Flamion, Bruno [UCL] Reginster, Jacques [UCL]
Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2008
Language Anglais
Journal information "Osteoporosis International : with other metabolic bone diseases" - Vol. 19, no. 9, p. 1247-1250 (2008)
Peer reviewed yes
Publisher Springer London Ltd (Artington)
issn 0937-941X
e-issn 1433-2965
Publication status Publié
Affiliations UCL - Cliniques universitaires Saint-Luc
UCL
Keywords bone mineral density ; bridging study ; glucocorticoid-induced osteoporosis ; men ; phase III studies ; postmenopausal women
Links
  1. van Staa T.P., Use of oral corticosteroids in the United Kingdom, 10.1093/qjmed/93.2.105
  2. Canalis E, Bilezekian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593–598
  3. van Staa TP, Leufkens HGM, Cooper C (2002) A meta-analysis of the epidemiology of corticosteroid-induced osteoporosis. Osteoporos Int 13:777–787
  4. van staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol 39:1383–1389
  5. Van Staa T, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000
  6. Laan Roland F. J. M., Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis : A Randomized, Controlled Study, 10.7326/0003-4819-119-10-199311150-00001
  7. Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899
  8. Luengo M., Picado C., del Rio L., Guañabens N., Montserrat J. M., Setoain J., Treatment of Steroid-induced Osteopenia with Calcitonin in Corticosteroid-dependent Asthma: A One-Year Follow-up Study, 10.1164/ajrccm/142.1.104
  9. van Staa TP, Laan RF, Barton IP, Cohen S, Reid DR, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229
  10. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97–103
  11. Bresssot C, Meunier PJ, Chapuy MC et al (1979) Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1:303–311
  12. Dempster DW (1989) Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137–147
  13. Dempster DW, Arlot MA, Meunier PJ (1983) Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410–417
  14. Compston JE, Reginster J-Y, Avouac B et al (1996) Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis. Calcif Tissue Int 59:323–327
  15. Abadie EC, Devogelaer J-P, Ringe JD et al (2005) Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Sem Arthritis Rheum 35:1–4
  16. Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New Engl J Med 339:292–299
  17. Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42:2309–2318
  18. Reid DM, Hughes RA, Laan RFJM et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trial. J Bone Miner Res 15:1006–1013
  19. Orwoll ES, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. New Engl J Med 343:604–610
  20. Bobba R, Adachi JD (2007) Review of the safety and efficacy for the treatment of male osteoporosis. Clin Interv Aging 2:275–282
  21. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17
Bibliographic reference Compston, J. ; Devogelaer, Jean-Pierre ; Reid, D. M. ; Boisdron, J. ; Brandi, M. -L. ; et. al. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. In: Osteoporosis International : with other metabolic bone diseases, Vol. 19, no. 9, p. 1247-1250 (2008)
Permanent URL http://hdl.handle.net/2078.1/36976